Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
DeLeon TT, Almquist DR, Kipp BR, Langlais BT, Mangold A, Winters JL, Kosiorek HE, Joseph RW, Dronca RS, Block MS, McWilliams RR, Kottschade LA, Rumilla KM, Voss JS, Seetharam M, Sekulic A, Markovic SN, Bryce AH.
DeLeon TT, et al. Among authors: langlais bt.
PLoS One. 2020 Mar 20;15(3):e0230306. doi: 10.1371/journal.pone.0230306. eCollection 2020.
PLoS One. 2020.
PMID: 32196516
Free PMC article.